Quarterly report · Q3
3034.TEDINET S100Q6EO
Period2022-04-01 → 2022-12-31
Filed2023-02-13
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥126.1bn | 2022-04-01 → 2022-12-31 | Cons. | Net sales |
| Revenue | ¥166.2bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥124.5bn | 2021-04-01 → 2021-12-31 | Cons. | Net sales |
| Operating income | ¥6.8bn | 2022-04-01 → 2022-12-31 | Cons. | Operating income |
| Operating income | ¥6.9bn | 2021-04-01 → 2021-12-31 | Cons. | Operating income |
| Ordinary income | ¥7.1bn | 2022-04-01 → 2022-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥10.1bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥7.1bn | 2021-04-01 → 2021-12-31 | Cons. | Ordinary income |
| Profit before tax | ¥7.1bn | 2022-04-01 → 2022-12-31 | Cons. | Income before income taxes |
| Profit before tax | ¥7.1bn | 2021-04-01 → 2021-12-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥4.2bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥5.5bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥4.2bn | 2021-04-01 → 2021-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥4.2bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss |
| Net income | ¥4.2bn | 2021-04-01 → 2021-12-31 | Cons. | Profit loss |
| Total assets | ¥105.5bn | at 2022-12-31 | Cons. | Assets |
| Total assets | ¥96.0bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥103.0bn | at 2021-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥58.3bn | at 2022-12-31 | Cons. | Liabilities |
| Total liabilities | ¥52.1bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥47.3bn | at 2022-12-31 | Cons. | Net assets |
| Net assets / equity | ¥43.9bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥42.4bn | at 2021-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥26.0bn | at 2022-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥16.7bn | at 2022-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥112.57 | 2022-04-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥48.43 | 2022-10-01 → 2022-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥149.51 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥113.26 | 2021-04-01 → 2021-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥46.26 | 2021-10-01 → 2021-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 44.8% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 45.7% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 41.1% | at 2021-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 30
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-12-31 | −¥317m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-12-31 | −¥317m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-12-31 | −¥2.6bn |
| jpcrp040300-q3r_E03476-000Health Insurance Pharmacyreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥115.4bn |
| jpcrp040300-q3r_E03476-000Health Insurance Pharmacyreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥115.3bn |
| jpcrp040300-q3r_E03476-000Health Insurance Pharmacyreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥66m |
| jpcrp040300-q3r_E03476-000Health Insurance Pharmacyreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥8.3bn |
| jpcrp040300-q3r_E03476-000Medical Relatedreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥11.1bn |
| jpcrp040300-q3r_E03476-000Medical Relatedreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥10.8bn |
| jpcrp040300-q3r_E03476-000Medical Relatedreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥250m |
| jpcrp040300-q3r_E03476-000Medical Relatedreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥1.2bn |
| —segment total | revenue | 2022-04-01 → 2022-12-31 | ¥126.4bn |
| —segment total | revenue external | 2022-04-01 → 2022-12-31 | ¥126.1bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥317m |
| —segment total | segment profit | 2022-04-01 → 2022-12-31 | ¥9.4bn |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-12-31 | −¥308m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-12-31 | −¥308m |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-12-31 | −¥2.4bn |
| jpcrp040300-q3r_E03476-000Health Insurance Pharmacyreportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥114.9bn |
| jpcrp040300-q3r_E03476-000Health Insurance Pharmacyreportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥114.9bn |
| jpcrp040300-q3r_E03476-000Health Insurance Pharmacyreportable segment | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥46m |
| jpcrp040300-q3r_E03476-000Health Insurance Pharmacyreportable segment | segment profit | 2021-04-01 → 2021-12-31 | ¥8.4bn |
| jpcrp040300-q3r_E03476-000Medical Relatedreportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥9.9bn |
| jpcrp040300-q3r_E03476-000Medical Relatedreportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥9.7bn |
| jpcrp040300-q3r_E03476-000Medical Relatedreportable segment | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥261m |
| jpcrp040300-q3r_E03476-000Medical Relatedreportable segment | segment profit | 2021-04-01 → 2021-12-31 | ¥930m |
| —segment total | revenue | 2021-04-01 → 2021-12-31 | ¥124.9bn |
| —segment total | revenue external | 2021-04-01 → 2021-12-31 | ¥124.5bn |
| —segment total | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥308m |
| —segment total | segment profit | 2021-04-01 → 2021-12-31 | ¥9.3bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 367
| Item | Context | Value | Unit |
|---|---|---|---|
| Year to quarter end consolidated statement of comprehensive income (text) | CurrentYTDDuration | Text · Plus | |
| Notes additional information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Debtors notes regarding overdraft contracts and or loan commitments (text) | CurrentQuarterInstant | Text · Plus | |
| Notes regarding gain on reversal of provision for withdraw loss from employees pension fund (text) | CurrentYTDDuration | Text · Plus | |
| Description of fact that quarterly statement of cash flows has not been prepared (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1YTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | Prior1YTDDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant events after reporting period quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |